174 related articles for article (PubMed ID: 19273351)
1. Nuclear receptor ligands in therapy of cholestatic liver disease.
Sturm E; Wagner M; Trauner M
Front Biosci (Landmark Ed); 2009 Jan; 14(11):4299-325. PubMed ID: 19273351
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G; Trauner M
Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
[TBL] [Abstract][Full Text] [Related]
3. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
Zollner G; Marschall HU; Wagner M; Trauner M
Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
[TBL] [Abstract][Full Text] [Related]
4. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
5. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
Wagner M; Trauner M
Ann Hepatol; 2005; 4(2):77-99. PubMed ID: 16010241
[TBL] [Abstract][Full Text] [Related]
7. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
8. [Cholestasis and cholestatic liver diseases].
Poupon R
Gastroenterol Clin Biol; 2009; 33(8-9):778-88. PubMed ID: 19556086
[TBL] [Abstract][Full Text] [Related]
9. [Role of PXR and CAR in cholestasis].
Suh JI
Korean J Hepatol; 2006 Mar; 12(1):5-15. PubMed ID: 16565602
[TBL] [Abstract][Full Text] [Related]
10. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis.
Stahl S; Davies MR; Cook DI; Graham MJ
Xenobiotica; 2008 Jul; 38(7-8):725-77. PubMed ID: 18668429
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.
Stedman CA; Liddle C; Coulter SA; Sonoda J; Alvarez JG; Moore DD; Evans RM; Downes M
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2063-8. PubMed ID: 15684063
[TBL] [Abstract][Full Text] [Related]
12. Nuclear receptors as drug targets in cholestatic liver diseases.
Halilbasic E; Baghdasaryan A; Trauner M
Clin Liver Dis; 2013 May; 17(2):161-89. PubMed ID: 23540496
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease.
Kakizaki S; Takizawa D; Tojima H; Horiguchi N; Yamazaki Y; Mori M
Front Biosci (Landmark Ed); 2011 Jun; 16(8):2988-3005. PubMed ID: 21622216
[TBL] [Abstract][Full Text] [Related]
14. Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease.
Kakizaki S; Takizawa D; Tojima H; Yamazaki Y; Mori M
Curr Drug Targets; 2009 Nov; 10(11):1156-1163. PubMed ID: 19925451
[TBL] [Abstract][Full Text] [Related]
15. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
16. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
17. FXR and PXR: potential therapeutic targets in cholestasis.
Jonker JW; Liddle C; Downes M
J Steroid Biochem Mol Biol; 2012 Jul; 130(3-5):147-58. PubMed ID: 21801835
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of cholestasis.
Zollner G; Trauner M
Wien Med Wochenschr; 2006 Jul; 156(13-14):380-5. PubMed ID: 16937039
[TBL] [Abstract][Full Text] [Related]
19. Bile salt excretory pump: biology and pathobiology.
Suchy FJ; Ananthanarayanan M
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
[TBL] [Abstract][Full Text] [Related]
20. New molecular insights into the mechanisms of cholestasis.
Wagner M; Zollner G; Trauner M
J Hepatol; 2009 Sep; 51(3):565-80. PubMed ID: 19595470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]